Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16725-1 · Cited by 571 · cited 2×
“…follow-up) have shown that high levels of direct protection are maintained 4 years after vaccination in children immunized between the ages of 5 months and 18 years, but the effectiveness wanes to low levels after only 1 year in children immunized at 2, 3 and 4 months of age (Trotter et al., 2004).”
Self-citationMaiden, M. C., & Stuart, J. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08679-8 · Cited by 418 · cited 1×
“…UK, clinical trials and the licensure of meningococcal C conjugate (MCC) vaccines were accelerated in response to increasing morbidity and mortality from serogroup C disease, and the first MCC vaccines were licensed in 1999 on the basis of safety and immunogenicity studies (Miller et al., 2001).”
Background
Cited by
Global epidemiology of meningococcal disease
Harrison, L. H., Trotter, C. L., & Ramsay, M. E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.063 · Cited by 755
Self-citationNeisseria meningitidis: Biology, Microbiology, and Epidemiology
Rouphael, N. G., & Stephens, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-346-2_1 · Cited by 425
Trotter, C. L., & Maiden, M. C. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.48 · Cited by 203
Self-citationPelton, S. I. (2016) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2016.04.012 · Cited by 199
The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014
Whittaker, R., Dias, J. G., Ramliden, M., Ködmön, C., Economopoulou, A., Beer, N., Pastore Celentano, L., Kanitz, E., Richter, L., Mattheus, W., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.007 · Cited by 179
“007 on pathogen carriage, herd protection, and the duration of protection are also important [9,31], but may not be fully understood at the time policy decisions are made.”
BackgroundInfluential
Metadata
- Authors
- Trotter, C. L., & Ramsay, M. E.
- Venue
- FEMS Microbiology Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01
- Volume
- 31
- Issue
- 1
- Pages
- 101-107
- ISSN
- 0168-6445 (ISSN-L)
- 1574-6976
- OpenAlex
- W2008438078
- Cited by
- 160
- References
- 2
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. https://app.cochat.ai/papers/10.1111/j.1574-6976.2006.00053.x
- The paper
- Trotter, C. L., & Ramsay, M. E. (2007). Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiology Reviews. https://doi.org/10.1111/j.1574-6976.2006.00053.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.